Bayer tags U.S. site for sale, jeopardizing up to 300 jobs; India nixing bulk-drug price controls;

@FiercePharma: Galderma's North American president Francois Fournier gets the profile treatment from D magazine . Profile | Follow @FiercePharma

> Bayer HealthCare plans to sell a facility in Indiana, potentially putting close to 300 people out of work, local media reports. News

> India will end price controls on bulk drugs in an attempt to keep its drugmakers from abandoning API production and allowing Chinese companies to fill the gap. Story

> Pfizer ($PFE) won European approval for its drug Vyndaqel to treat a rare neurodegenerative disease, Transthyretin Familial Amyloid Polyneuropathy. Release

> Incyte's Jakafi pill won the FDA nod as a treatment for myelofibrosis, a rare bone-marrow disease, becoming the first drug approved for that condition. Article

> Chinese officials fined two pharma middlemen for cornering the market on an active ingredient, which drove up the cost of a blood-pressure medicine subject to government price controls. Story

> Hospira ($HSP) launched a generic version of Merck's ($MRK) antibiotic drug Primaxin in the U.S. Report

> Cadence Pharmaceuticals raised about $67 million in a stock offering to finance marketing of its fever and pain treatment Ofirmev. News

> The Generic Pharmaceutical Association spent $548,315 lobbying Washington in the third quarter on issues such as budget cuts and healthcare reform. Story

> U.S.-based Polaris plans to plough $50 million into a new cancer-drug production facility in Taiwan. Article

> PharMerica's poison pill may yield the biggest price increase in takeover history as Omnicare continues to pursue a buyout. News

> South African health activists are trying to persuade the government to use WTO powers to promote generic versions of on-patent meds. Report

Biotech News

@FierceBiotech: Pfizer won expert backing for Prevnar 13 in adults for pneumonia, meningitis and other pneumococcus bacteria diseases. Item | Follow @FierceBiotech

@JohnCFierce: EC aims at boosting antibiotic R&D with a public/private initiative, via Reuters . Report | Follow @JohnCFierce

@RyanMFierce: Agios attracts 3 large public investors, Celgene and VCs in $78M C round. Story | Follow @RyanMFierce

> Agios adds $78M C round to back cancer drug portfolio. Item

Vaccines News

> FDA experts back Pfizer's Prevnar 13 for older adults. Article

> GAVI to bring HPV vaccines to poor countries. Story

> Experts: Video on Delta flights misleading about vaccines. News

> Weakness found in deadly malaria parasite. Report

Manufacturing News

> Aesica CEO Hardy makes CDMO business fly. News

> Novartis workers strike to forestall plant closure. Item

> Merck leans on suppliers, partners to expand reach. Article

> Strikers want Dr. Reddy promise of regular work. Story

> UCB to set up major bioprocessing plant in Switzerland. Report

And Finally... Drug resistance is growing in Europe, with rates in some bacteria approaching 50%, European public health officials said. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.